"Our goal is to make immunotherapy benefit the majority of cancer patients, not just a few"
Jennifer Wu, PhD. President
CanCure is drug development company dedicated to fighting cancer using novel strategies that harness the power of the human immune system. CanCure currently focuses on taking its leading product CuraB-10 into clinic in the very near future. CuraB-10 is at IND-enabling ready stage.
CuraB-10 is a first-in-class immune stimulatory monoclonal antibody targeting a tumor-released immune suppressive molecule soluble MIC (sMIC). In preclinical animal studies, CuraB-10 monotherapy effectively reduces tumor size and prolongs overall survival. CuraB-10 also enhances tumor response to immune checkpoint blocking therapies (nivolumab, pembrolizumab, and ipilimumab) when used in combination, and elicits a positive response even in tumors that failed to respond to these therapies.
A Change in Cancer Therapeutics
Driven by innovation CanCure is poised to change the landscape of cancer therapeutics.